{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:42:18Z","timestamp":1793374938288,"version":"4.5.0"},"reference-count":147,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jjcc.2025.09.018","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:50:18Z","timestamp":1759539018000},"page":"128-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antiarrhythmic potential of SGLT2 inhibitors: Mechanistic insights and clinical evidence"],"prefix":"10.1016","volume":"87","author":[{"given":"Shinya","family":"Fujiki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2025.09.018_bb0005","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"Sglt2 inhibition--a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0010","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0025","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0030","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0035","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0040","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0045","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0055","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0065","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0070","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0075","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa2500366","article-title":"Dapagliflozin in patients undergoing transcatheter aortic-valve implantation","volume":"392","author":"Raposeiras-Roubin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0080","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1152\/physrev.00024.2019","article-title":"Cardiac transmembrane ion channels and action potentials: cellular physiology and arrhythmogenic behavior","volume":"101","author":"Varr\u00f3","year":"2021","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccep.2010.10.012","article-title":"Overview of basic mechanisms of cardiac arrhythmia","volume":"3","author":"Antzelevitch","year":"2011","journal-title":"Card Electrophysiol Clin"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0090","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1253\/circj.CJ-20-1212","article-title":"JCS\/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias","volume":"86","author":"Ono","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0095","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/1573403X14666180111145207","article-title":"Oxidative stress and cardiac remodeling: an updated edge","volume":"14","author":"Rababa\u2019h","year":"2018","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0100","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41577-022-00714-3","article-title":"Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19","volume":"22","author":"Lazzerini","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0105","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s42444-024-00110-z","article-title":"Inflammation and arrhythmogenesis: a narrative review of the complex relationship","volume":"25","author":"Taghdiri","year":"2024","journal-title":"Int J Arrhythm"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0110","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jacep.2023.02.019","article-title":"Autonomic nervous system and cardiac metabolism: links between autonomic and metabolic remodeling in atrial fibrillation","volume":"9","author":"Chakraborty","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0115","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1161\/CIRCEP.108.817320","article-title":"Cardiac metabolism and arrhythmias","volume":"2","author":"Barth","year":"2009","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cells11182915","article-title":"Disturbed cardiac metabolism triggers atrial arrhythmogenesis in diabetes mellitus: energy substrate alternate as a potential therapeutic intervention","volume":"11","author":"Lkhagva","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0125","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.yjmcc.2007.05.012","article-title":"Stretch-induced MAP kinase activation in cardiac myocytes: differential regulation through beta1-integrin and focal adhesion kinase","volume":"43","author":"Lal","year":"2007","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s42444-022-00065-z","article-title":"Electrolyte\u2019s imbalance role in atrial fibrillation: pharmacological management","volume":"23","author":"Rafaqat","year":"2022","journal-title":"Int J Arrhythm"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0135","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","article-title":"Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart","volume":"467","author":"Vrhovac","year":"2015","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0140","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0145","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jcb.10631","article-title":"Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1)","volume":"90","author":"Zhou","year":"2003","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0150","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","article-title":"Direct cardiac effects of SGLT2 inhibitors","volume":"21","author":"Chen","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0155","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.freeradbiomed.2013.05.035","article-title":"Role of oxidants on calcium and sodium movement in healthy and diseased cardiac myocytes","volume":"63","author":"Sag","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coph.2017.03.005","article-title":"Cardiomyocyte Ca(2+) homeostasis as a therapeutic target in heart failure with reduced and preserved ejection fraction","volume":"33","author":"Peana","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0165","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.3390\/ijms22157976","article-title":"Cardioprotection by SGLT2 inhibitors-Does it all come down to Na(+)?","volume":"22","author":"Trum","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0170","article-title":"Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: a mini review","volume":"9","author":"Wu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1011429","article-title":"Benefits of SGLT2 inhibitors in arrhythmias","volume":"9","author":"Gao","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0180","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects","volume":"167","author":"Dyck","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0185","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1152\/physrev.1997.77.1.51","article-title":"Molecular physiology of vertebrate Na+\/H+ exchangers","volume":"77","author":"Wakabayashi","year":"1997","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcmgh.2016.09.010","article-title":"Pathophysiology of intestinal Na(+)\/H(+) exchange","volume":"3","author":"Gurney","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0195","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/phrs.2001.0908","article-title":"Role of the cardiac Na(+)\/H(+)exchanger in [Ca(2+)](i)and [Na(+)](i)handling during intracellular acidosis. Effect of cariporide (Hoe 642)","volume":"45","author":"Salameh","year":"2002","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0200","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3349\/ymj.2016.57.5.1252","article-title":"Oxidative stress-activated NHE1 is involved in high glucose-induced apoptosis in renal tubular epithelial cells","volume":"57","author":"Wu","year":"2016","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0205","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.yjmcc.2009.12.007","article-title":"Ca(2+)\/calmodulin-dependent protein kinase II contributes to intracellular pH recovery from acidosis via Na(+)\/H(+) exchanger activation","volume":"49","author":"Vila-Petroff","year":"2010","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000350120","article-title":"Sgk1-dependent stimulation of cardiac Na+\/H+ exchanger Nhe1 by dexamethasone","volume":"32","author":"Voelkl","year":"2013","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112515","article-title":"Empagliflozin reduces oxidative stress through inhibition of the novel inflammation\/NHE\/[Na(+)](c)\/ROS-pathway in human endothelial cells","volume":"146","author":"Uthman","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0220","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/CIRCRESAHA.108.175141","article-title":"Activation of Na+\/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure","volume":"103","author":"Nakamura","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0225","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0008-6363(02)00809-X","article-title":"Increased Na+\/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model","volume":"57","author":"Baartscheer","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0230","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1161\/01.RES.0000014966.97486.C0","article-title":"Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice","volume":"90","author":"Engelhardt","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0235","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/bjp.2008.189","article-title":"Chronic inhibition of the Na+\/H+ \u2212 exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling","volume":"154","author":"Baartscheer","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0240","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0245","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s42003-023-04663-y","article-title":"The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice","volume":"6","author":"Choi","year":"2023","journal-title":"Commun Biol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0250","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s13238-020-00809-4","article-title":"Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis","volume":"13","author":"Jiang","year":"2022","journal-title":"Protein Cell"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0255","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s12276-023-01002-3","article-title":"Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction","volume":"55","author":"Kim","year":"2023","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0260","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10557-021-07311-x","article-title":"Empagliflozin ameliorates ouabain-induced Na(+) and Ca(2+) dysregulations in ventricular myocytes in an Na(+)-dependent manner","volume":"37","author":"Peng","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0265","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1002\/ehf2.13024","article-title":"Empagliflozin inhibits Na(+) \/H(+) exchanger activity in human atrial cardiomyocytes","volume":"7","author":"Trum","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0270","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0275","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1093\/cvr\/cvab129","article-title":"Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na+\/H+ exchanger 1: persistent inhibition under various experimental conditions","volume":"117","author":"Zuurbier","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0280","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00395-024-01067-9","article-title":"Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2","volume":"119","author":"Chen","year":"2024","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104781","article-title":"Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium","volume":"157","author":"Cappetta","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0290","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abp9952","article-title":"SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant","volume":"15","author":"Guo","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0295","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","article-title":"Dapagliflozin attenuates Na(+)\/H(+) exchanger-1 in cardiofibroblasts via AMPK activation","volume":"32","author":"Ye","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0300","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1093\/cvr\/cvaa323","article-title":"Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart","volume":"117","author":"Chung","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1179131","article-title":"Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells","volume":"14","author":"Chen","year":"2023","journal-title":"Front Physiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173040","article-title":"Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice","volume":"875","author":"Ganbaatar","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0315","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1038\/s41598-020-64380-y","article-title":"Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats","volume":"10","author":"Kuno","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0320","article-title":"Sodium glucose co-transporter 2 inhibitors ameliorate endothelium barrier dysfunction induced by cyclic stretch through inhibition of reactive oxygen species","volume":"22","author":"Li","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0325","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","article-title":"Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure","volume":"13","author":"Byrne","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0330","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.31264","article-title":"Empagliflozin, a sodium-glucose cotransporter inhibitor enhancing mitochondrial action and cardioprotection in metabolic syndrome","volume":"239","author":"Li","year":"2024","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.177147","article-title":"Empagliflozin prevents TNF-\u03b1 induced endothelial dysfunction under flow -the potential involvement of calcium and sodium-hydrogen exchanger","volume":"986","author":"Li","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0340","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ehf2.12003","article-title":"The late sodium current in heart failure: pathophysiology and clinical relevance","volume":"1","author":"Horvath","year":"2014","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0345","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tcm.2015.05.006","article-title":"Late sodium current: A mechanism for angina, heart failure, and arrhythmia","volume":"26","author":"Makielski","year":"2016","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0350","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/CIRCULATIONAHA.115.017980","article-title":"Late I(Na) in the heart: Physiology, pathology, and pathways","volume":"132","author":"Makielski","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0355","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1085\/jgp.95.3.411","article-title":"Kinetic analysis of single sodium channels from canine cardiac Purkinje cells","volume":"95","author":"Scanley","year":"1990","journal-title":"J Gen Physiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0360","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s11064-017-2314-9","article-title":"Forty years of sodium channels: structure, function, pharmacology, and epilepsy","volume":"42","author":"Catterall","year":"2017","journal-title":"Neurochem Res"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0365","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1113\/jphysiol.2014.281428","article-title":"Na+ channel function, regulation, structure, trafficking and sequestration","volume":"593","author":"Chen-Izu","year":"2015","journal-title":"J Physiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0370","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.yjmcc.2013.03.001","article-title":"The late Na current as a therapeutic target: where are we?","volume":"61","author":"Maier","year":"2013","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0375","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","article-title":"Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy","volume":"127","author":"Coppini","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0380","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1113\/jphysiol.2013.256461","article-title":"Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological, molecular and genetic aspects","volume":"591","author":"Remme","year":"2013","journal-title":"J Physiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0735-1097(00)00716-6","article-title":"The long QT syndromes: genetic basis and clinical implications","volume":"36","author":"Chiang","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0390","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2174\/09298673113209990220","article-title":"Late sodium current inhibition: the most promising antiarrhythmic principle in the near future?","volume":"21","author":"Frommeyer","year":"2014","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0395","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-3-642-41588-3_7","article-title":"The role of late I Na in development of cardiac arrhythmias","volume":"221","author":"Antzelevitch","year":"2014","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0400","article-title":"Empagliflozin attenuates myocardial sodium and calcium dysregulation and reverses cardiac remodeling in streptozotocin-induced diabetic rats","volume":"20","author":"Lee","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0405","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","article-title":"Cardiac late sodium channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor empagliflozin","volume":"143","author":"Philippaert","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0410","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.yjmcc.2024.11.014","article-title":"The sodium\/glucose cotransporter 2 inhibitor empagliflozin inhibits long QT 3 late sodium currents in a mutation specific manner","volume":"198","author":"Lunsonga","year":"2025","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0415","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/CIRCULATIONAHA.121.057237","article-title":"Empagliflozin reverses late Na(+) current enhancement and cardiomyocyte proarrhythmia in a translational murine model of heart failure with preserved ejection fraction","volume":"145","author":"Hegyi","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0420","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cvr\/cvae095","article-title":"Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF","volume":"120","author":"Trum","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0425","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.2147\/DDDT.S418321","article-title":"SGLT1: A potential drug target for cardiovascular disease","volume":"17","author":"Zhao","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175720","article-title":"Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function","volume":"949","author":"Dasari","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0435","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/jpet.116.232025","article-title":"Interaction of the sodium\/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2","volume":"358","author":"Ohgaki","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0440","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature04710","article-title":"hERG potassium channels and cardiac arrhythmia","volume":"440","author":"Sanguinetti","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0445","doi-asserted-by":"crossref","first-page":"E2134","DOI":"10.1073\/pnas.1109370109","article-title":"Dynamic reciprocity of sodium and potassium channel expression in a macromolecular complex controls cardiac excitability and arrhythmia","volume":"109","author":"Milstein","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0450","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1152\/physrev.00014.2006","article-title":"Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation","volume":"87","author":"Nattel","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0455","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1161\/hh1101.091193","article-title":"Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness","volume":"88","author":"Pogwizd","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0460","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.3390\/cells10113203","article-title":"Arrhythmogenic remodeling in the failing heart","volume":"10","author":"Husti","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0465","doi-asserted-by":"crossref","DOI":"10.3390\/cells11233707","article-title":"Empagliflozin and dapagliflozin increase Na(+) and inward rectifier K(+) current densities in human cardiomyocytes derived from induced pluripotent stem cells (hiPSC-CMs)","volume":"11","author":"Dago","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0470","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12933-018-0790-0","article-title":"A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats","volume":"17","author":"Durak","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0475","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179559","article-title":"SGLT2 inhibitor empagliflozin modulates ion channels in adult zebrafish heart","volume":"23","author":"Karpushev","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0480","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25115701","article-title":"Electrophysiological effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor dapagliflozin on human cardiac potassium channels","volume":"25","author":"M\u00fcller","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0485","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.jacc.2020.10.005","article-title":"Effect of empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction","volume":"76","author":"Omar","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0490","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF Trial","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0495","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00392-022-02049-4","article-title":"Body fluid regulation via chronic inhibition of sodium-glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial","volume":"112","author":"Fujiki","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0500","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0505","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","article-title":"Twenty-four-hour blood pressure-lowering effect of a sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA Study","volume":"139","author":"Kario","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0510","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jjcc.2024.02.002","article-title":"Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes: a sub-analysis of the PROTECT trial","volume":"84","author":"Kusunose","year":"2024","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0515","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-024-02369-x","article-title":"Effect of extracellular matrix stiffness on efficacy of dapagliflozin for diabetic cardiomyopathy","volume":"23","author":"Zhu","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0520","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0525","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jacc.2018.12.064","article-title":"Autonomic nervous system dysfunction: JACC focus seminar","volume":"73","author":"Goldberger","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0530","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0535","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022637","article-title":"Different responses of muscle sympathetic nerve activity to dapagliflozin between patients with type 2 diabetes with and without heart failure","volume":"10","author":"Hamaoka","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0540","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-019-0914-1","article-title":"Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction","volume":"18","author":"Zhang","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0545","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0550","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/dom.13577","article-title":"Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk","volume":"21","author":"Kim","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0555","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/CIRCULATIONAHA.122.060402","article-title":"Metabolomic profiling of the effects of dapagliflozin in heart failure with reduced ejection fraction: DEFINE-HF","volume":"146","author":"Selvaraj","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0560","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12933-024-02309-9","article-title":"Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial","volume":"23","author":"Fujiki","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0565","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0570","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.carpath.2005.01.005","article-title":"Cardiac remodeling and failure: From molecules to man (Part II)","volume":"14","author":"Fedak","year":"2005","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0575","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1161\/CIRCULATIONAHA.122.062021","article-title":"Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, controlled EMPA-VISION trial","volume":"147","author":"Hundertmark","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0580","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0585","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-020-01048-x","article-title":"The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study","volume":"19","author":"Chen","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0590","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12933-021-01243-4","article-title":"SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system","volume":"20","author":"Bonora","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0595","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 Trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0600","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0605","article-title":"Protective effects of sodium-glucose transporter 2 inhibitors on atrial fibrillation and atrial flutter: a systematic review and meta- analysis of randomized placebo-controlled trials","volume":"12","author":"Li","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0610","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12933-020-01105-5","article-title":"SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials","volume":"19","author":"Li","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0615","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","article-title":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0620","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022222","article-title":"Sodium-glucose co-transporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Pandey","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0625","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.21037\/jtd-22-550","article-title":"The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation\/atrial flutter in patients with type 2 diabetes mellitus\/heart failure: a systematic review and meta-analysis","volume":"14","author":"Wang","year":"2022","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0630","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/FJC.0000000000001222","article-title":"Are high- or low-dose SGLT2 inhibitors associated with cardiovascular and respiratory adverse events? A meta-analysis","volume":"79","author":"Zou","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0635","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1097\/FJC.0000000000001183","article-title":"Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials","volume":"79","author":"Zheng","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0640","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/dom.14772","article-title":"Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis","volume":"24","author":"Li","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0645","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s10741-022-10281-3","article-title":"Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation\/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials","volume":"28","author":"Sfairopoulos","year":"2023","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0650","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacep.2022.08.004","article-title":"Efficacy of sodium-glucose cotransporter 2 inhibitors on outcomes after catheter ablation for atrial fibrillation","volume":"8","author":"Kishima","year":"2022","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0655","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/jce.16621","article-title":"The impact of SGLT2 inhibitors on atrial fibrillation recurrence and long-term clinical outcomes in HFrEF patients undergoing cryoballoon ablation: a new frontier beyond diabetes and heart failure","volume":"36","author":"Cetin","year":"2025","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0660","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.hrthm.2024.08.034","article-title":"Impact of sodium-glucose cotransporter 2 inhibitor on recurrence and cardiovascular outcomes after catheter ablation for atrial fibrillation in patients with heart failure","volume":"22","author":"Zhao","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0665","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/jce.16544","article-title":"Impact of sodium-glucose co-transporter 2 inhibitors on atrial fibrillation recurrence post-catheter ablation among patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"36","author":"Abdelhadi","year":"2025","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132359","article-title":"Effectiveness of sodium-glucose co-transporter 2 inhibitors on atrial fibrillation recurrence after catheter ablation: A systemic review and meta-analysis","volume":"413","author":"Zhang","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0675","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/ejhf.2381","article-title":"Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF","volume":"24","author":"Butt","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0680","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ejhf.2861","article-title":"Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation","volume":"25","author":"Filippatos","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0685","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-023-01860-1","article-title":"Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review","volume":"22","author":"Ouyang","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0690","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/jce.15894","article-title":"SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Meta-analysis of randomized clinical trials","volume":"34","author":"Oates","year":"2023","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0695","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/eurjpc\/zwad356","article-title":"Sodium-glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis","volume":"31","author":"Zhang","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0700","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","article-title":"Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF","volume":"42","author":"Curtain","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0705","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/europace\/euab177","article-title":"Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials","volume":"24","author":"Sfairopoulos","year":"2022","journal-title":"Europace"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0710","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13643-025-02766-7","article-title":"Redefining outcomes of ventricular arrhythmia for SGLT2 inhibitor medication in heart failure patients: a meta-analysis of randomized controlled trials","volume":"14","author":"Lin","year":"2025","journal-title":"Syst Rev"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0715","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12933-024-02137-x","article-title":"Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of>80,000 patients (the SGLT2i-Arrhythmias and Sudden Cardiac Death)","volume":"23","author":"Liao","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0720","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400147","article-title":"Ertugliflozin to reduce arrhythmic burden in patients with ICDs\/CRT-Ds","volume":"3","author":"Benedikt","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0725","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/ehf2.15223","article-title":"SGLT2i reduce arrhythmic events in heart failure patients with cardiac implantable electronic devices","volume":"12","author":"Mariani","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0730","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jjcc.2024.09.005","article-title":"Impact on ventricular arrhythmic burden of SGLT2 inhibitors in patients with chronic heart failure evaluated with cardiac implantable electronic device monitoring","volume":"85","author":"Basile","year":"2025","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2025.09.018_bb0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107759","article-title":"Effects of SGLT2i therapy on cardiac electrophysiological properties and arrhythmias in diabetic patients with implantable cardiac defibrillator","volume":"216","author":"Sardu","year":"2025","journal-title":"Pharmacol Res"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508725002485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508725002485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T04:21:04Z","timestamp":1769919664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508725002485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":147,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0914508725002485"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2025.09.018","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiarrhythmic potential of SGLT2 inhibitors: Mechanistic insights and clinical evidence","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2025.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese College of Cardiology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}